Member Info for CHELSEA7

6.20/6.50

100k sell, 50k sell and 14k buy

MMs taking 50k at 6.275

Buys 210k

Sells 16k

MMs taking 120k at 6.265..........................blue by Monday IMHO

2 Nice buys

155k at 6.44 followed by a 50k buy same.

Buys 100k

Sells 70k

Up to 120k at 6.226

Wins/Scap.................A 100K Buy at 6.46................nice to see.

70k at 6.26

120k at 6.226

Opened 6.20/6.80, and WINS taking just 60k at 6.225.

Yesterday 5 MMs were taking just 11k at 6.50.............................186k sell later at 6.50, we ticked down, lol!!!

Well the volume was up yesterday, but just the 2 buys 2,222 and 30k. LSE Level 2 was showing 10 trades, only 8 were declared, and WINS and SCAP are on the bid and ask respectively, where we saw much of the larger trades a few weeks ago.

After the tick down to 6.20 WINS were taking just 35k shares at 6.21, which rose to 120k at 6.225 by the close. Hoping that rises and a buyer emerges again. Set up for a trend reversal? Heaven knows, but MMs wanting shares again, encouraging.

Tuesday 15 October, 2019
Sanofi
Sanofi opens its first digitally-enabled, continuous manufacturing facility; ushers in next generation of biotech manufacturing

https://www.investegate.co.uk/sanofi/gnw/sanofi-opens-its-first-digitally-enabled--continuous-manufacturing-facility--ushers-in-next-generation-of-biotech-manufacturing/20191015060000H7962/

Hmmm, $3m a week sounds better, lol.

I hadn"t really understood the overheads and growth Bionech have made since they were launched back in 2008. Must equate to $3m a day over that period needed for funding alone to get them where they are today, and the disappointment they must feel in having to raise just 20% of what was originally planned in the IPO must have been a major disappointment to them, and showed too how much they needed the additional funding, as the option was to put off the round until better market conditions. It puts it into a real perspective when we consider the £4m Vulpes raise was enough to pay our overheads for just over a year. I believe their cash in hand is in the region of $500m so indeed another raising wil be made, I could do worse than try and understand the complexities of these serie rounds to get the full picture, but certainly not surprised to see they have fallen a bit since the IPO.

Well my hope this morning was for a better week than the last couple, and once again with 5 MMs taking 11k shares at 6.50 we saw far more actually taken and duly saw red for our efforts. Hard to see at the moment at what price we will see some buying , all seems so dependant on the type of news we get, even when. A possible error on Level 2, theyare showing 10 trades, just eight were executed/posted, feels like its an error mself and we just saw a 19k sell at 6.21 after the bid ticked down, and the bid closed at 6.225 for 120k shares at the end.

So till tomorrow again, irritating to see our rise to 10p erode such as it has, I think many of us were hoping for a series of good RNSs to consolidate that rise and even take it higher, hoping we don"t have to wait too long for that to happen though, an RNS this week would be very welcome.

Night guys,

30.679

Volume 238k

Buys 33k

Sells 205k

Taking 120k now at 6.225, could be a couple of trades to be posted.

Will take 37k at 6.21

6.20/6.60

Tick Down...............6.50/6.60

6 sells in quich succession at 6.50 totalling 188k shares.............so much for taking 11k shares only!!

Just Panmure left on bid at 6.5p, just might see a decent buy at 6.60?

6.50/6.80

5 MMs will take 11k at 6.5?

Very good posts guys, regardless of which a very good week last week. Even Fridays 8% down wasn"t so bad after the rises of the week . With profit taking and fears of a "no reason"" RNS.

Hope it continues for you.......ATB

Morning Crumbs/All, yeah I guess I was, was really trying to remind us of the experience she has brought with her from Immunacore I can only imagine how delighted Lindy was to welcome her on board.

Have a good day, another very wet one here, here is to a better week..................

Bermudashorts,

In that field for sure, this article from Fierce Biotech last January..................

Samantha Paston has ended her long association with Immunocore to take up the head of research position at Scancell. Paston’s appointment is part of a broader effort by Scancell to add experience as it steps up its immunotherapy development activities.

Scancell is developing anticancer candidates based on two immunotherapy platforms, ImmunoBody and Moditope. The pipeline of ImmunoBody vaccines, led by clinical-phase NY-ESO-1 asset SCIB1, has advanced furthest, but the other platform has attracted attention and a T-cell receptor (TCR) deal with BioNTech.

With Scancell gearing up for trials and stepping up its TCR activities, the British biotech has added Paston to its team. Paston joined Avidex, the company that became Immunocore via an acquisition and spinout, straight after earning her doctorate in 2006 and stayed on throughout the early changes and more recent upheavals.

WEBINAR
CIOs’ Perspectives: Driving Clinical Trial Innovation with a Unified Platform
IT is being challenged with either trying to fix and maintain an already complex system of solution integrations, or exploring driving business impact by unifying its systems under one platform. Attend and learn about the IT benefits to shifting resources away from disparate systems and moving towards a unified platform.
REGISTER TODAY
The upshot is that Paston has worked at Immunocore since it was founded in 2008. Having started out as a senior research scientist, Paston went on to lead the T cell cloning and cell biology groups during her 11 years at the TCR specialist. Paston will now apply this experience to the emerging range of R&D tasks facing Scancell.

"Samantha will be invaluable in immunological design of the upcoming trials and spearheading the new TCR therapeutics,”

Lindy Durrant, Scancell’s founder and chief scientific officer, said in a statement. Paston will report directly to Durrant.

Scancell revealed news of Paston’s appointment alongside details of its new head of manufacturing. Adrian Parry, formerly head of small molecule CMC at Mereo BioPharma, has taken up the post, giving Scancell an employee with experience managing outsourced GMP production of clinical trial materials at a time when its manufacturing needs are growing.

Exactly that work? Well no, as I added...................Absolutely Rats, surprises me that a key member of Immunacores Research can leave the company and set up elsewhere with a Platform that was being developed with them. I thought there was something called Patents that would make that very unstraightforward.

Absolutely Rats, surprises me that a key member of Immunacores Research can leave the company and set up elsewhere with a Platform that was being developed with them. I thought there was something called Patents that would make that very unstraightforward. We should remember to that Immunacores financial position was not in its best state when she left.

We read so much about the change of key personnel, CEOs etc in the Big Pharmas every year, good to know we have enticed someone of Samanthas potential to us. Some ask do big Pharma know who we are, well it seems Lindy knows who in big Pharma to headhunt for our benefit, and it could well be a relationship between the two that perhaps led Samantha to us.

Lindy is not short of plaudits amongst us LTHs, but she is up there with every new treatment and who is leading the Research on their behalf. I cannot imagine a few years back Scancell being in a position to attract such senior staff as now, and it seems big progress is being made in the Manufacturing side with Adrian Parry at the helm too. Seeing the tangible results from our last two big appointments is a huge sign of what is to come, and at times like this comforting to know what is and might be happening behind the scenes.

There a few commercial deals that seem realistic at this time, over and above SCIB1/2 and Moditope, which could very well fund us throuh full trials and expenditure without the need for going to the market. Already we are funded to early 2021, a luxury we haven"t had for some considerable time, and when I talk of a good stratagy I mean with good fortune our funding could be secured for much longer, and start including other platforms in clinical development.

It is shame we are in a period where patience is really needed again, volumes are so low almost negidgable, but it is good to reming ourselves what we are being patient for, in these times. It is pretty pointless guessing when news will come, it can come at any time, but is essential to remind ourselves what we are being patient for. I have been doing that to a degree this weekend, wanted to ensure I kept away from speculating on speculation, we all know timelines set up at the AGM and we can just hope those will be on target. There is much going on at Scancell quite apart from just trials, which can easily get forgotten whilst the share has retreated 50% from the highs we saw after Vulpes appointment. I don"t believe it will take too much to see a return to those levels. Just MO.